dissociation constant K_D in the range of 10^{-8} M to 10^{-2} M, in the range of 10^{-7} M to 10^{-3} M or in the range of 10^{-6} M to 10^{-3} M; and /or said polypeptides P1 and P2 have, in the presence of said substrate or cell, with each other a dissociation constant K_D below 10^{-6} M, below 10^{-7} M below 10^{-8} M or below 10^{-9} M.

5. The set of polypeptides according to any one of claims 1 to 4, wherein said antigen A1 and/or said antigen A2 is an antigen expressed on the surface of cells of a tumour or on the surface of progenitor/precursor cells of a tumour.

6. The set of polypeptides according to any one of claims 1 to 5, wherein the combination of antigen A1 and antigen A2 is only found on cancerous cells, and not on cells that are not cancerous.

7. The set of polypeptides according to claim 6, wherein the combination of antigen A1 and antigen A2 is specific for cancerous cells of a certain type of cancer.

8. The set of polypeptides according to any one of claims 1 to 7, wherein said antigen A1 is an MHC antigen being an allelic variant selected from the group consisting of:
HLA-A2, HLA-Cw6, HLA-A1, HLA-A3, HLA-A25, HLA-B7, HLA-B8, HLA-B35, HLA-B44, HLA-Cw3, HLA-Cw4, and HLA-Cw7; and/or

said antigen A2 is an antigen that is specific for a certain cell type or cell lineage selected from the group consisting of:
CD45; CD34; CD33; CD138; CD15; CD1a; CD2; CD3; CD4; CD5; CD8; CD20; CD23; CD31; CD43; CD56; CD57; CD68; CD79a; CD146; surfactant proteins; synaptophysin; CD56; CD57; nicotinic acetylcholine receptor; muscle-specific kinase MUSK; voltage-gated calcium channel (P/Q-type); voltage-gated potassium channel (VGKC); N-methyl-D-aspartate receptor (NMDA); TSH; amphiphysin; HepPar-1; ganglioside GQ1B, GD3 or GM1; and glycophorin-A.

9. The set of polypeptides according to any one of claims 1 to 8, wherein any of said antigens A1 and A2 is selected from the group consisting of:
HLA-A2; HLA-Cw6; EpCAM; CD20; CD33; CD38; CD45; Her2; EGFR; CD138; CEA; CD19; PSMA; E-cadherin; Ca-125; Her-2/neu; gross cystic disease fluid protein; BCA-225; CA 19-9; CD117; CD30; Epithelial antigen BER-EP4, Epithelial membrane antigen and Epithelial Related Antigen MOC-31; Epidermal growth factor

(xxi) one of said antigens A1 and A2 is CD45 or CD38 and the other one is CD138;

(xxii) one of said antigens A1 and A2 is EGFR and the other one is CEA;

(xxiii) one of said antigens A1 and A2 is Her2 and the other one is CEA; or

(xxiv) one of said antigens A1 and A2 is CD19 and the other one is a clonotypic antibody on the surface of a B cell.

11. The set of polypeptides according to any one of claims 1 to 10, wherein said targeting moiety T1 and/or T2 comprises an immunoglobulin module; or
wherein said targeting moiety T1 and/or T2 comprises an aptamer or a natural ligand of said antigen A1 or antigen A2, respectively.

12. The set of polypeptides according to claim 11, wherein said targeting moiety T1 comprises an immunoglobulin module I1 comprising a V_L domain linked to a V_H domain or comprising a variable domain V_HH of a llama antibody, camel antibody or shark antibody; and/or
said targeting moiety T2 comprises an immunoglobulin module I2 comprising a V_L domain linked to a V_H domain or comprising a variable domain V_HH of a llama antibody, camel antibody or shark antibody.

13. The set of polypeptides according to claim 12, wherein said immunoglobulin module I1 comprises a scFv (single-chain variant fragment), a Fab or a $F(ab')_2$ of an antibody or a complete antibody; and/or
said immunoglobulin module I2 comprises a scFv (single-chain variant fragment), a Fab or a $F(ab')_2$ of an antibody or a complete antibody.

14. The set of polypeptides according to any one of claims 1 to 4 and 7 to 13, wherein any one of said targeting moiety T1 and T2 comprises an allergen or substrate which binds to a clonotypic antibody on the surface of a B cell.

15. The set of polypeptides according to any one of claims 1 to 14, wherein said functional domain F is or comprises an immunoglobulin module, or a fluorescent molecule, or a molecule capable of mediating bioluminescence.

16. The set of polypeptides according to claim 15, wherein said functional domain F is a Fv (variant fragment) or a scFv (single-chain variant fragment) of an antibody.